Literature DB >> 11161275

Vaccination of chronic hepatitis B virus carriers with preS2/S envelope protein is not associated with the emergence of envelope escape mutants.

Patrick Soussan1, Stanislas Pol1, Florianne Garreau1, Christian Bréchot1, Dina Kremsdorf1.   

Abstract

PreS2/S vaccination of chronic hepatitis B virus (HBV) carriers led to a reduction in HBV replication or clearance of virus in 30% of treated patients. This study assessed whether vaccinotherapy of chronic HBV carriers induced the selection of escape mutants in the envelope 'a' determinant and whether envelope genetic variability might affect the response to vaccination. No amino acid differences were observed in the 'a' determinant between sequences obtained before and after treatment (five responders and seven non-responders). However, alignment with HBV prototype sequences revealed seven amino acid changes. Two mutations (T140S and P127L) diverged from subtype variations. In the complete envelope sequence (five non-responders and five responders), ten amino acid modifications were detected between sequences obtained before and after treatment. The absence of any common mutations did not enable the definition of a hot spot of mutations implicated in the response to vaccination. Moreover, vaccinotherapy does not induce the selection of escape mutants in the 'a' determinant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161275     DOI: 10.1099/0022-1317-82-2-367

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Transactivating effect of complete S protein of hepatitis B virus and cloning of genes transactivated by complete S protein using suppression subtractive hybridization technique.

Authors:  Gui-Qin Bai; Yan Liu; Jun Cheng; Shu-Lin Zhang; Ya-Fei Yue; Yan-Ping Huang; Li-Ying Zhang
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

2.  Screening of hepatocyte proteins binding to complete S protein of hepatitis B virus by yeast-two hybrid system.

Authors:  Gui-Qin Bai; Jun Cheng; Shu-Lin Zhang; Yan-Ping Huang; Lin Wang; Yan Liu; Shu-Mei Lin
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

3.  Study of transactivating effect of pre-S2 protein of hepatitis B virus and cloning of genes transactivated by pre-S2 protein with suppression subtractive hybridization.

Authors:  Dong Ji; Jun Cheng; Guo-Feng Chen; Yan Liu; Lin Wang; Jiang Guo
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

4.  Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study.

Authors:  Ming-Wei Lai; Chao-Wei Hsu; Chih-Lang Lin; Rong-Nan Chien; Wey-Ran Lin; Chi-Sheng Chang; Kung-Hao Liang; Chau-Ting Yeh
Journal:  Hepatol Int       Date:  2018-08-07       Impact factor: 6.047

Review 5.  Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis: an update.

Authors:  Raymond S Koff
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.487

6.  Molecular characterization of HBV strains circulating among the treatment-naive HIV/HBV co-infected patients of eastern India.

Authors:  Debraj Saha; Ananya Pal; Avik Biswas; Rajesh Panigrahi; Neelakshi Sarkar; Dipanwita Das; Jayeeta Sarkar; Subhasish Kamal Guha; Bibhuti Saha; Sekhar Chakrabarti; Runu Chakravarty
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.